NCT00211484View on ClinicalTrials.gov

Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

March 31, 2007

Conditions
Age-Related Macular Degenerations.Subfoveal Neovascularization.
Interventions
DRUG

Anecortave Acetate

Trial Locations (1)

10021

Manhattan Eye, Ear & Throat Hospital, New York

Sponsors

Collaborators (1)

Alcon Research
All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

lead

Manhattan Eye, Ear & Throat Hospital

OTHER

NCT00211484 - Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care. | Biotech Hunter | Biotech Hunter